Fermer le menu


Member of Lyonbiopole


Based in Lyon, France, AMOEBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution appears to be an alternative to the chemical treatments traditionally used in industry.

AMOEBA continues with its regulatory procedures so as to launch a request for provisional MA in the first half of 2016 for all European countries as soon as ANSES (French Agency for Food, Environmental and Occupational Health & Safety) has validated AMOEBA's solution for application in air-cooled towers.

In a worldwide market of chemical biocides estimated to be worth 21 bn€, AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT) estimated at 1.7 bn€. Its disruptive technology complies with new regulations in terms of environmental chemical emissions. AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC Small index on 21 September last.


Strategic application domain: Medical Technologies

Application market: Others

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Others

Created on july 21st, 2010 - 40 employees



38 avenue des Frères Montgolfier 69680 CHASSIEU



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.